Drugs in Dev. Dermatology
Phase I
Iceland 
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)
Details : AVT04 is the second proposed biosimilar product from Alvotech entering clinical studies, the first being AVT02, a proposed biosimilar to Humira®.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ustekinumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
